AbCellera Biologics Inc. (ABCL) Social Stream
AbCellera Biologics Inc (ABCL) Price Targets From Analysts
Use the tables below to see what analysts covering AbCellera Biologics Inc think about its future price and what recommendations they have for investors and traders.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-01-07 | 5 | $45 | $25 | $33 | $9.08 | 263.44% |
| 2021-11-09 | 4 | $55 | $25 | $45.25 | $9.08 | 398.35% |
| 2021-11-09 | 4 | $53 | $25 | $42.75 | $9.08 | 370.81% |
| 2021-11-09 | 5 | $53 | $25 | $42.75 | $9.08 | 370.81% |
| 2021-12-05 | 5 | $53 | $25 | $40.8 | $9.08 | 349.34% |
| 2021-12-05 | 6 | $53 | $25 | $40.8 | $9.08 | 349.34% |
| 2021-12-19 | 7 | $53 | $25 | $39.833 | $9.08 | 338.69% |
| 2021-12-21 | 7 | $53 | $25 | $38 | $9.08 | 318.5% |
| 2021-12-21 | 7 | $45 | $25 | $33 | $9.08 | 263.44% |
The Trend in the Analyst Price Target
Over the past 40 weeks, ABCL's average price target has gone down $19.4.
ABCL reports an average of 123.64% for its upside potential over the past 50 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-08-05 | 2 | 55 | 25 | 47.20 | 15.61 | 202.37% |
| 2021-11-09 | 5 | 53 | 25 | 42.75 | 14.71 | 190.62% |
| 2021-08-28 | 2 | 55 | 25 | 45.40 | 17.58 | 158.25% |
| 2021-11-09 | 5 | 55 | 25 | 45.25 | 14.71 | 207.61% |
| 2021-11-09 | 4 | 53 | 25 | 42.75 | 14.71 | 190.62% |
ABCL Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1 | 5 | 0 | 0 | 0 | 0 | 5 |
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- ABCL has a higher upside potential (average analyst target price relative to current price) than 844.62% of all US stocks.
- AbCellera Biologics Inc's variance in analysts' estimates is lower than -644.51% of all US stocks.
- To contextualize these metrics, consider that out of stocks in the large market cap category, AbCellera Biologics Inc's number of analysts covering the stock is higher than 95.24% of them.
- ABCL has a higher average analyst price target than 186.33% of stocks in the large market cap category.
In the Pharmaceutical Products industry, VIR, VCEL, and TIL are the three stocks most similar to AbCellera Biologics Inc regarding the price target and analyst recommendation information presented here.
Make investment decisions regarding ABCL using the data that counts. Try POWR Ratings for free.